• Like
MM&M Feature: Social Etiquette
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

MM&M Feature: Social Etiquette

  • 783 views
Published

 

Published in Health & Medicine , Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
783
On SlideShare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. PATIENT MARKETING REPORT Social Media SOCIAL Just as it followed other sectors into CRM, the pharma industry must find entry points into the online patient conversation. Gil Bashe explores some of the issues, hurdles ETIQUETTE and opportunities of Web 2.0 A ccessibility of online product and disease-state information that impact patient care. Recently, breast cancer groups have lauded has paved the way for a new era of patient interaction—and Genentech for engaging in a dialogue. a new era in branding and communications. Online adherents, of course, also include scores of people with Well-known brands once offered a beacon of light in a complex mainstream conditions, searching for information about diseases that problem/solution world. Brands such as Claritin or Allegra, Zocor or Lipitor, Viagra or Levitra, helped patients open the “what ails them” Pfizer sponsored a 10-part discussion with their doctors and clarify drug choice. Now, tiered series of scientists’ video co-pays, generic selection, pharmacy incentives and Part D plans diaries on BigThink.com (left) are diminishing the importance of “brand” in the heads, hearts and while Johnson & Johnson wallets of the consumer. And pharma marketers are experimenting created a YouTube channel with a less brand-specific approach to online patient communication. featuring information videos Suddenly, non-branded “disease-awareness” is back in marketing mode. Do consumers notice or care any longer? The model may seem counterintuitive for an industry so steeped in brand names, but brand managers who want to be more than mere spectators in driving online patient dialogue are going behind the brand. Their tack involves communications geared toward treatment discovery for small patient groups, commitment to achieving greater compliance and conveying pharma’s societal benefits. The patient is in DTC and Internet access have given permission for patients to con- nect 24/7. While content is still king, patient-to-patient communica- tions are enjoying newfound credibility. Online disease communities enable patients to consult fellow patients as one might consult a clinician. In the wake of diabetes and heart treatments under siege, who is more believable—physicians or peers? Nonprofits can be a first line of outreach for pharma to connect with a smaller patient base. Patient support and advocacy groups are a trusted source of information on disease states. Focusing on building relationships with these groups can give companies a seat at the table. It works both ways—pharma companies should allow these patients to have a voice within the corporation on decisions mmm-online.com ❘ OCTOBER 2008 ❘ MM&M 43
  • 2. PATIENT MARKETING REPORT had once been a mystery. But there’s potential and peril. “The danger is that if you search hard enough, you can find anything you want,” says Mike McDougall, director of corporate communications, Bausch & Lomb. That’s why specific forums moderated by a respected third party have an advantage over generic chat rooms with unverified information. “In the moderated rooms, that information becomes more authoritative. That’s the way organizations with a potential to brand can become beacons of trust in this realm.” Reality show Just as pharma followed other industries into customer-relationship management (CRM), industry is following other sectors into Web 2.0 and using the web to reinforce compliance messaging. Moderators on GlaxoSmithKline’s Alli Circles Community counsel that Alli is a program and requires patients to rethink eating habits, choose food with lower fat content, eat three meals a day, do physician As the host of online weight loss community Alli Circles, GSK is activity and not to take anti-diarrhea meds—steps designed to man- required to report all adverse events to the FDA age side effects. GSK leverages the engagement to affect confidence and minimize the number of patients stopping treatment. MD, is an example. Comments are welcome, subject to approval. As the host of Alli Circles, GSK must report adverse events to Through the videos, J&J communicates about topics people care the FDA. Once, sponsoring a site run by a third party might have about, and becomes a partner in promoting good health. mitigated some of the “credibility” hurdles. Today, that’s not always In a similar vein, Quest Diagnostics has used Web 2.0 in its aim to the case…being the hidden Wizard of Oz can diminish a site’s cred- up compliance with annual colorectal cancer screening. Its disease ibility and bring congressional inquiry. That’s one of the reasons intervention awareness and prevention campaign tugs at the heart- pharma leaders are prepared to go it alone. strings of people by asking them to e-mail a cancer screening aware- Johnson & Johnson’s (J&J) YouTube channel, where users can ness video to their friends and loved ones. The video garnered nearly download health information videos featuring Nancy Snyderman, 200,000 views, targeting a variety of demographic segments. One new venue for distributing content—the video interview portal BigThink.com—uses its idea showcase as a way to engage Connecting with micro-patient groups online with potential customers in a non-brand-specific way. BigThink is an The Scleroderma Foundation sees its role as that of online idea lab that streams a daily stew of philosophers and PhDs, information champion. “Not to endorse any specific professors and poets. Now add pharma to the mix. treatments,” explains Foundation CEO Frannie Wal- Earlier this year, BigThink landed its first pharma sponsor: Pfizer, dron (pictured), “but to inform our patients of every- for a 10-part series featuring company scientists sharing their personal thing out there.” That includes conveying information histories and reflecting on challenges. Just a few clicks cue up a Pfizer on new treatments and clinical advances. pharmacologist’s view of developing drugs for the global community There are about 300,000 scleroderma patients and a scientist’s advice for the next generation of researchers. in the US, one-third of whom live with the systemic Like its consumer-generated counterparts, BigThink has learned kind—the most serious of the two forms of the the importance of holding a transparent forum. Sponsors may worry autoimmune disorder, affecting internal organs like the lungs and kidneys, as well as skin, and causing gastrointestinal, circulatory and that their social-media effort may be commandeered by naysayers, other issues. yet feedback is a vital part of the Internet. This is a good first rule for Orphan illnesses like these, with fewer than 200,000 patients, often the industry in general: If you go forward with candor and honesty, form the basis for tightly knit online communities. Once connected by making clear your support and why you’re doing it, you don’t have irregular snail-mail newsletters, these groups have found the web to be to worry as much about negative comments. an equal-opportunity, 24/7 connector. Patients, their families and physi- Pharma should also choose a moderator carefully: Pick someone cians are creating support groups to share breaking clinical informa- who will understand an issue and speak to it authoritatively and out- tion, news on helpful therapies and new clinical trials. side the sponsors’ interests. Also, rethink the metrics beyond unique Waldron urges companies to consider foundations a prime route for clicks and time spent within an area. Sometimes bringing together outreach. “With organizations, there’s an opportunity for companies to the right people, who in turn host their own sites and blogs, creates educate the patient base about information and support,” she says. Specialty company Actelion, maker of the drug Tracleer (bosentan) the tipping point of patient knowledge and understanding. for treating pulmonary hypertension, works with the Scleroderma Pharma can establish a bigger footprint in this evolving terrain. Foundation to raise awareness of its Sure Steps patient support That could mean the kind of engagement longed for by industry—a program. To get the word out, Actelion advertises on the foundation’s truly collaborative connection with patient advocates and info seek- website, scleroderma.org, and in its e-newsletter and print magazine. ers. If pharma can fashion itself as a partner in health, providing all While maintaining distance from the Foundation and its patient base, it supplementary information to guide fair-balance choices and the path enables patients to find out more about the medication their physicians to living well, it’s going to loom large in the minds of consumers. use to help manage symptoms. Collaboration helps place patients a few clicks away from the information they seek. Gil Bashe is EVP, director of the health practice, Makovsky + Co. mmm-online.com ❘ OCTOBER 2008 ❘ MM&M 45